Company Overview of Greer Laboratories, Inc.
Greer Laboratories, Inc. develops and manufactures allergy immunotherapy products for treating humans and animals in the United States. The company’s human allergy products include extracts, sterile diluents and sterile empty vials, safety syringes, syringes and syringe trays, vial racks, skin testing devices, and ancillary products. Its veterinary allergy products include extracts, sterile diluents and sterile empty vials, syringes and syringe trays, vial racks, and ancillary products. The company also provides source materials, including mites, pollens, fungi and smuts, venoms, food source materials, insects, dust, miscellaneous, and custom products, as well as epithelia, dander, hair, and...
639 Nuway Circle NE
PO Box 800
Lenoir, NC 28645
Founded in 1904
Key Executives for Greer Laboratories, Inc.
Chief Executive Officer and President
Chief Financial Officer and Vice President
Vice President of Operations
Executive Vice President of Sales & Marketing and Executive Vice President of Commercial Operations
Executive Vice President of Research & Development
Compensation as of Fiscal Year 2014.
Greer Laboratories, Inc. Key Developments
GREER Laboratories, Inc. Announces Executive Changes
Nov 13 14
GREER Laboratories, Inc. announced the appointment of Rick Russell as President and CEO. Russell serves as CEO of Ares Allergy Holdings, Inc. Russell joins the company following the departure of former President and CEO John Roby, who is leaving the company to pursue other opportunities. Prior to joining Ares and GREER, Russell served as Executive Vice President and Chief Commercial Officer at Sunovion Pharmaceuticals. Prior to his time at Sunovion, he held the position of U.S. Executive Vice President, Neurodegenerative Diseases and Rheumatology at EMD Serono and also served as Vice President Marketing at Sanofi-Aventis.
GREER(R) Laboratories, Inc. Announces FDA Approval of ORALAIR(R)
Apr 1 14
GREER(R) Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ORALAIR(R) (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet. ORALAIR(R) is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for grass pollen-specific IgE antibodies for any of the five grass species contained in the product. ORALAIR(R) is approved for use in persons 10 through 65 years of age. Allergy immunotherapy in the United States has traditionally been administered via a series of subcutaneous injections in the allergy specialist's office. The approval of ORALAIR(R) provides an additional option for allergy specialists and patients to consider for treating grass allergies. Grass allergies are the most common seasonal allergy in the United States(1,2) and most people are allergic to more than one type of grass.(3) ORALAIR(R) is the only FDA approved oral allergy immunotherapy tablet that includes a five grass, mixed pollens allergen extract. These five grasses provide a wide range of grass allergy coverage in the United States. ORALAIR(R) is a tablet that dissolves under the tongue. The first dose is taken in the doctor's office under medical supervision, and subsequent doses are administered once a day by the patient or the patient's caregiver. ORALAIR(R) should be started four months before the expected onset of each grass pollen season and treatment continued throughout the season. ORALAIR(R) may reduce grass allergy symptoms for patients within the first allergy season that it is taken. The ORALAIR(R) clinical program was based on safety, efficacy and tolerability results from an extensive set of clinical trials which included, in both the United States and Europe, over 2,500 adults and children. ORALAIR(R) was generally well tolerated and the most common adverse events (reported in >=5% of patients) were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. GREER holds exclusive U.S. commercialization rights to ORALAIR(R) through its partnership with STALLERGENES, developer and manufacturer of the product.
GREER Announces Data from its Pivotal Phase III Investigational Clinical Trial for GREER Sublingual Allergy Immunotherapy Liquid
Mar 10 14
GREER announced that data from its pivotal Phase III investigational clinical trial for GREER(R) Sublingual Allergy Immunotherapy Liquid (SAIL)(TM) is published in the March issue of the Journal of Allergy and Clinical Immunology. The study marks the first successful North American Phase III clinical trial to demonstrate the safety and efficacy of a sublingual standardized ragweed allergen immunotherapy liquid extract. The objective of the study was to determine the efficacy and tolerability of GREER(R) SAIL(TM) Standardized Short Ragweed extract in subjects with ragweed-related allergic rhinoconjunctivitis. The randomized, multi-center, double-blind, placebo-controlled, parallel group Phase III trial included 429 participants, ages 18-55 years, across 26 centers in North America. Participants had a minimum 2-year history of moderate to severe allergic rhinoconjunctivitis attributable to ragweed pollen that normally required anti-allergy medications. During the entire season, there was a 43% decrease in the total combined (symptom + medication use) score (TCS) relative to placebo (p=0.0005). Similar decreases were observed in the secondary endpoints in TCS between the two groups during peak season (42%) and in daily symptom scores during the entire (42%) and peak (41%) seasons.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 3, 2015